High-Dose Folinic Acid and 5-Fluorouracil in the Treatment of Advanced Colon Cancer

This meta-analysis is based on 106 évaluations of response from 77 clinical studies about 5-fluorouracil (5FU) treatment with or without leucovorin (LV) in metastatic colorectal carcinoma. Overall, in naive patients, LV is associated with a médian response rate of 31% as compared with a 12% flgure with 5FU alone.Using a forward stepwise multilinear régression analysis, it is shown that as much as 44% of the variance in the reported response rates in naive patients can be accounted for by treatment-related variables (P < 0.001). The significant parameters are LV adjunction (partial R = 0.636), cumulative total 5FU dose (R = 0.344), and 5FU weekiy schedule (R = 0.246). In pretreated patients, the latter parameter is the only significant one (R = 0.443). Unexpectediy, LV administration behaves like an all-or-nothing governor, without any obvions dose-effect relationship.P rotracted 5FU infusion over weeks allows a mean cumulative drug delivery, 3 times higher than bolus regimens (21.3 vs 7.02 g m"^, P < 0.001) and may represent the best clinical approach to influence the 5FUrelated variables. Accordingly, it is suggested that SFU protracted infusion, titrated to the highest tolerable doses and potentiated with low doses of leucovorin, could represent the most efficacious way for using SFU in colorectal disseminated cancer. This hypothesis and its eventual impact on survival should be tested in randomized trials.

show abstract

The Emerging Role of 5-Fluorouracil and Leucovorin in the Treatment of Advanced Breast Cancer. A Review

Zaniboni

1989

Journal of Chemotherapy

View full text Add to dashboard Cite

Considerable interest has been generated by the clinical experience with 5-fluorouracil + leucovorin based regimens in colorectal cancer. Consequently, this combination was tested in other tumors in which 5-fluorouracil has some activity (gastric, pancreatic, head and neck and breast cancer). This review summarizes the interesting results reported so far in advanced breast cancer. Up to now, more than 300 patients have been treated with chemotherapeutic regimens based on this attempt at biochemical modulation of 5-fluorouracil's activity. Overall, a median response rate of 26% was achieved by nine studies performed in 245 mainly pretreated patients with an acceptable degree of toxicity. Moreover, two additional studies explored the clinical activity of this combination as first-line chemotherapy for advanced disease with impressive results. Current efforts to further improve the therapeutic index of this combination will also be briefly discussed.

show abstract

High-Dose Folinic Acid and 5-Fluorouracil in the Treatment of Advanced Colon Cancer

Cited by 4 publications

References 0 publications

Chemotherapeutische Strategien beim kolorektalen Karzinom — Eine Übersicht

Chemotherapeutische Strategien beim kolorektalen Karzinom — Eine Übersicht

5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? multivariate meta-analysis of the literature

The Emerging Role of 5-Fluorouracil and Leucovorin in the Treatment of Advanced Breast Cancer. A Review

Contact Info

Product

Resources

About